Forte Biosciences (FBRX) Operating Expenses (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Operating Expenses of $22.4 million for Q1 2026, up 39.17% year-over-year from $16.1 million in Q1 2025, and down 8.68% quarter-over-quarter from $24.6 million in Q4 2025.
Forte Biosciences (FBRX) Operating Expenses (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Operating Expenses for 11 consecutive years, with $22.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 39.17% year-over-year to $22.4 million; the TTM figure through Mar 2026 stood at $77.0 million (up 71.35% YoY), while the FY2025 annual figure was $70.7 million, up 93.04% from the prior year.
- Operating Expenses retreated to $22.4 million in Q1 2026 per FBRX's latest filing, from $24.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $24.6 million in Q4 2025 and bottomed at $2.5 million in Q1 2022.
- Historically, Operating Expenses has averaged $10.4 million across 5 years, with a median of $8.6 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Expenses plunged 55.54% — and 2025, when it soared 234.25%.
- Forte Biosciences' Operating Expenses stood at $4.9 million in 2022, then rose by 29.2% to $6.4 million in 2023, then rose by 15.2% to $7.4 million in 2024, then jumped by 234.25% to $24.6 million in 2025, then fell by 8.68% to $22.4 million in 2026.
- Business Quant data shows FBRX's Operating Expenses at $22.4 million in Q1 2026, $24.6 million in Q4 2025, and $18.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | 24.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.60 Mn |
| Mar 31, 2026 | 22.44 Mn |
| Dec 31, 2025 | 24.57 Mn |
| Sep 30, 2025 | 18.38 Mn |
| Jun 30, 2025 | 11.58 Mn |
| Mar 31, 2025 | 16.12 Mn |
| Dec 31, 2024 | 7.35 Mn |
| Sep 30, 2024 | 8.63 Mn |
| Jun 30, 2024 | 12.82 Mn |
| Mar 31, 2024 | 7.80 Mn |
| Dec 31, 2023 | 6.38 Mn |
| Sep 30, 2023 | 10.22 Mn |
| Jun 30, 2023 | 9.03 Mn |
| Mar 31, 2023 | 6.86 Mn |
| Dec 31, 2022 | 4.94 Mn |
| Sep 30, 2022 | 3.42 Mn |
| Jun 30, 2022 | 3.02 Mn |
| Mar 31, 2022 | 2.51 Mn |
| Dec 31, 2021 | 3.30 Mn |
| Sep 30, 2021 | 7.70 Mn |